Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Cardiovascular Event Risk in Rheumatoid Arthritis is Higher than in Type 2 Diabetes: a 15 Year Longitudinal Study.

Agca R, Hopman LHGA, Laan KCJ, van Halm VP, Peters MJL, Smulders YM, Dekker JM, Nijpels G, Stehouwer CDA, Voskuyl AE, Boers M, Lems WF, Nurmohamed MT.

J Rheumatol. 2019 May 15. pii: jrheum.180726. doi: 10.3899/jrheum.180726. [Epub ahead of print]

PMID:
31092721
2.

The relationship between remission and health-related quality of life in a cohort of SLE patients.

Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, van Tuyl LH, van Vollenhoven RF, Voskuyl AE.

Rheumatology (Oxford). 2019 Apr 1;58(4):628-635. doi: 10.1093/rheumatology/key349.

PMID:
30517706
3.

Systemic sclerosis: state of the art on clinical practice guidelines.

Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, Matucci-Cerinic M.

RMD Open. 2018 Oct 18;4(Suppl 1):e000782. doi: 10.1136/rmdopen-2018-000782. eCollection 2018.

4.

A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.

van Rhijn-Brouwer FCC, Gremmels H, Fledderus JO, Schuurman AH, Bonte-Mineur F, Vonk MC, Voskuyl AE, de Vries-Bouwstra JK, Coert JH, Radstake TRDJ, van Laar JM, Verhaar MC; MANUS Study Group.

BMJ Open. 2018 Aug 20;8(8):e020479. doi: 10.1136/bmjopen-2017-020479.

5.

[Myositis: more than a muscle disease].

Lim J, van Royen-Kerkhof A, Jonkers RE, Starink MV, Voskuyl AE, van der Kooi AJ.

Ned Tijdschr Geneeskd. 2018;162:D2312. Dutch.

PMID:
29473539
6.

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography.

Bruijnen STG, Verweij NJF, van Duivenvoorde LM, Bravenboer N, Baeten DLP, van Denderen CJ, van der Horst-Bruinsma IE, Voskuyl AE, Custers M, van de Ven PM, Bot JCJ, Boden BJH, Lammertsma AA, Hoekstra OSH, Raijmakers PGHM, van der Laken CJ.

Rheumatology (Oxford). 2018 Apr 1;57(4):770. doi: 10.1093/rheumatology/key034. No abstract available.

7.

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography.

Bruijnen STG, Verweij NJF, van Duivenvoorde LM, Bravenboer N, Baeten DLP, van Denderen CJ, van der Horst-Bruinsma IE, Voskuyl AE, Custers M, van de Ven PM, Bot JCJ, Boden BJH, Lammertsma AA, Hoekstra OSH, Raijmakers PGHM, van der Laken CJ.

Rheumatology (Oxford). 2018 Apr 1;57(4):631-638. doi: 10.1093/rheumatology/kex448. Erratum in: Rheumatology (Oxford). 2018 Apr 1;57(4):770.

8.

Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis.

Houben E, Groenland SL, van der Heijden JW, Voskuyl AE, Doodeman HJ, Penne EL.

BMC Nephrol. 2017 Dec 29;18(1):378. doi: 10.1186/s12882-017-0797-x.

9.

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.

Ter Wee MM, Coupé VM, den Uyl D, Blomjous BS, Kooijmans E, Kerstens PJ, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Boers M, Lems WF.

RMD Open. 2017 Oct 25;3(2):e000502. doi: 10.1136/rmdopen-2017-000502. eCollection 2017.

10.

Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study.

Kroese SJ, Abheiden CNH, Blomjous BS, van Laar JM, Derksen RWHM, Bultink IEM, Voskuyl AE, Lely AT, de Boer MA, de Vries JIP, Fritsch-Stork RDE.

J Immunol Res. 2017;2017:8245879. doi: 10.1155/2017/8245879. Epub 2017 Sep 28.

11.

Comprehensive approach to study complement C4 in systemic lupus erythematosus: Gene polymorphisms, protein levels and functional activity.

Tsang-A-Sjoe MWP, Bultink IEM, Korswagen LA, van der Horst A, Rensink I, de Boer M, Hamann D, Voskuyl AE, Wouters D.

Mol Immunol. 2017 Dec;92:125-131. doi: 10.1016/j.molimm.2017.10.004. Epub 2017 Oct 26.

PMID:
29080553
12.

Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies.

Houben E, Penne EL, Voskuyl AE, van der Heijden JW, Otten RHJ, Boers M, Hoekstra T.

Rheumatology (Oxford). 2018 Mar 1;57(3):555-562. doi: 10.1093/rheumatology/kex338. Review.

PMID:
29029294
13.

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Rheumatology (Oxford). 2017 Sep 1;56(9):1586-1596. doi: 10.1093/rheumatology/kex223.

PMID:
28859326
14.

Variability in quantitative analysis of atherosclerotic plaque inflammation using 18F-FDG PET/CT.

Lensen KDF, van Sijl AM, Voskuyl AE, van der Laken CJ, Heymans MW, Comans EFI, Nurmohamed MT, Smulders YM, Boellaard R.

PLoS One. 2017 Aug 11;12(8):e0181847. doi: 10.1371/journal.pone.0181847. eCollection 2017.

15.

An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.

Bossini-Castillo L, Campillo-Davó D, López-Isac E, Carmona FD, Simeon CP, Carreira P, Callejas-Rubio JL, Castellví I, Fernández-Nebro A, Rodríguez-Rodríguez L, Rubio-Rivas M, García-Hernández FJ, Madroñero AB, Beretta L, Santaniello A, Lunardi C, Airó P, Hoffmann-Vold AM, Kreuter A, Riemekasten G, Witte T, Hunzelmann N, Vonk MC, Voskuyl AE, de Vries-Bouwstra J, Shiels P, Herrick A, Worthington J, Radstake TRDJ, Martin J; Spanish Scleroderma Group.

J Rheumatol. 2017 Oct;44(10):1453-1457. doi: 10.3899/jrheum.161369. Epub 2017 Jul 1.

PMID:
28668810
16.

Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus.

van der Meulen PM, Barendregt AM, Cuadrado E, Magro-Checa C, Steup-Beekman GM, Schonenberg-Meinema D, Van den Berg JM, Li QZ, Baars PA, Wouters D, Voskuyl AE, Ten Berge IRJM, Huizinga TWJ, Kuijpers TW.

Rheumatology (Oxford). 2017 Aug 1;56(8):1407-1416. doi: 10.1093/rheumatology/kex073.

PMID:
28460084
17.

A multi-parameter response prediction model for rituximab in rheumatoid arthritis.

de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang-A-Sjoe M, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X.

Joint Bone Spine. 2018 Mar;85(2):219-226. doi: 10.1016/j.jbspin.2017.02.015. Epub 2017 Mar 28.

PMID:
28363827
18.

Prevalence of malnutrition and validation of bioelectrical impedance analysis for the assessment of body composition in patients with systemic sclerosis.

Spanjer MJ, Bultink IEM, de van der Schueren MAE, Voskuyl AE.

Rheumatology (Oxford). 2017 Jun 1;56(6):1008-1012. doi: 10.1093/rheumatology/kex014.

PMID:
28340004
19.

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.

van den Oever IAM, Heslinga M, Griep EN, Griep-Wentink HRM, Schotsman R, Cambach W, Dijkmans BAC, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters MJL, van Schaardenburg D, Nurmohamed MT.

Rheumatology (Oxford). 2017 Sep 1;56(9):1472-1478. doi: 10.1093/rheumatology/kew497.

PMID:
28199724
20.

Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort.

López-Isac E, Bossini-Castillo L, Palma AB, Assassi S, Mayes MD, Simeón CP, Ortego-Centeno N, Vicente E, Tolosa C, Rubio-Rivas M, Román-Ivorra JA, Beretta L, Moroncini G, Hunzelmann N, Distler JHW, Riemekasten G, de Vries-Bouwstra J, Voskuyl AE, Radstake TRDJ, Herrick A, Denton CP, Fonseca C, Martín J.

Arthritis Rheumatol. 2017 Jun;69(6):1337-1338. doi: 10.1002/art.40058. Epub 2017 May 9. No abstract available.

21.

Screening for renal involvement in ANCA-associated vasculitis: room for improvement?

Houben E, van der Heijden JW, van Dam B, Bax WA, Voskuyl AE, Penne EL.

Neth J Med. 2017 Jan;75(1):21-26.

22.

A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.

Carmona FD, Vaglio A, Mackie SL, Hernández-Rodríguez J, Monach PA, Castañeda S, Solans R, Morado IC, Narváez J, Ramentol-Sintas M, Pease CT, Dasgupta B, Watts R, Khalidi N, Langford CA, Ytterberg S, Boiardi L, Beretta L, Govoni M, Emmi G, Bonatti F, Cimmino MA, Witte T, Neumann T, Holle J, Schönau V, Sailler L, Papo T, Haroche J, Mahr A, Mouthon L, Molberg Ø, Diamantopoulos AP, Voskuyl A, Brouwer E, Daikeler T, Berger CT, Molloy ES, O'Neill L, Blockmans D, Lie BA, Mclaren P, Vyse TJ, Wijmenga C, Allanore Y, Koeleman BPC; Spanish CGA Group; UKGCA Consortium; Vasculitis Clinical Research Consortium, Barrett JH, Cid MC, Salvarani C, Merkel PA, Morgan AW, González-Gay MA, Martín J.

Am J Hum Genet. 2017 Jan 5;100(1):64-74. doi: 10.1016/j.ajhg.2016.11.013. Epub 2016 Dec 29.

23.

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).

van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, Askanase A, Balážová P, Bonfa E, Bootsma H, Boumpas D, Bruce I, Cervera R, Clarke A, Coney C, Costedoat-Chalumeau N, Czirják L, Derksen R, Doria A, Dörner T, Fischer-Betz R, Fritsch-Stork R, Gordon C, Graninger W, Györi N, Houssiau F, Isenberg D, Jacobsen S, Jayne D, Kuhn A, Le Guern V, Lerstrøm K, Levy R, Machado-Ribeiro F, Mariette X, Missaykeh J, Morand E, Mosca M, Inanc M, Navarra S, Neumann I, Olesinska M, Petri M, Rahman A, Rekvig OP, Rovensky J, Shoenfeld Y, Smolen J, Tincani A, Urowitz M, van Leeuw B, Vasconcelos C, Voss A, Werth VP, Zakharova H, Zoma A, Schneider M, Ward M.

Ann Rheum Dis. 2017 Mar;76(3):554-561. doi: 10.1136/annrheumdis-2016-209519. Epub 2016 Nov 24. Review.

24.

Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes.

Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Tsang-A-Sjoe MW, Bultink IE, Voskuyl AE, Bentlage AE, Vidarsson G, Wolbink G, Rispens T.

J Immunol. 2017 Jan 1;198(1):82-93. Epub 2016 Nov 18.

25.

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.

Bruijnen S, Tsang-A-Sjoe M, Raterman H, Ramwadhdoebe T, Vugts D, van Dongen G, Huisman M, Hoekstra O, Tak PP, Voskuyl A, van der Laken C.

Arthritis Res Ther. 2016 Nov 18;18(1):266.

26.

Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.

Tsang-A-Sjoe MW, Bultink IE, Heslinga M, Voskuyl AE.

Rheumatology (Oxford). 2017 Jan;56(1):121-128. doi: 10.1093/rheumatology/kew377. Epub 2016 Nov 1.

PMID:
27803306
27.

Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, Kerstens P, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):989-996. doi: 10.1002/acr.23112. Epub 2017 Jun 7.

28.

Off-label use of rituximab for systemic lupus erythematosus in Europe.

Rydén-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A, Colodro Ruiz A, Doria A, Dörner T, Gonzalez-Echavarri C, Gremese E, Houssiau FA, Huizinga T, Inanç M, Isenberg D, Iuliano A, Jacobsen S, Jimenéz-Alonso J, Kovács L, Mariette X, Mosca M, Nived O, Oristrell J, Ramos-Casals M, Rascón J, Ruiz-Irastorza G, Sáez-Comet L, Salvador Cervelló G, Sebastiani GD, Squatrito D, Szücs G, Voskuyl A, van Vollenhoven R.

Lupus Sci Med. 2016 Sep 6;3(1):e000163. doi: 10.1136/lupus-2016-000163. eCollection 2016.

29.

Extracranial giant cell arteritis: A narrative review.

Lensen KD, Voskuyl AE, Comans EF, van der Laken CJ, Smulders YM.

Neth J Med. 2016 Jun;74(5):182-92. Review.

30.

The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis.

Konijn NP, van Tuyl LH, Boers M, van de Ven PM, den Uyl D, Ter Wee MM, Kerstens P, Voskuyl AE, van Schaardenburg D, Lems WF, Nurmohamed MT.

Rheumatology (Oxford). 2016 Sep;55(9):1615-22. doi: 10.1093/rheumatology/kew221. Epub 2016 May 31.

PMID:
27247434
31.

Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.

Sanders JS, de Joode AA, DeSevaux RG, Broekroelofs J, Voskuyl AE, van Paassen P, Kallenberg CG, Tervaert JW, Stegeman CA.

Nephrol Dial Transplant. 2016 Sep;31(9):1453-9. doi: 10.1093/ndt/gfw211. Epub 2016 May 30.

PMID:
27242368
32.

Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies.

Ekholm L, Vosslamber S, Tjärnlund A, de Jong TD, Betteridge Z, McHugh N, Plestilova L, Klein M, Padyukov L, Voskuyl AE, Bultink IE, Michiel Pegtel D, Mavragani CP, Crow MK, Vencovsky J, Lundberg IE, Verweij CL.

Scand J Immunol. 2016 Aug;84(2):100-9. doi: 10.1111/sji.12449.

33.

Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies.

López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ; Spanish Scleroderma Group, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JH, Riekemasten G, van der Helm-van Mil AH, de Vries-Bouwstra J, Magro-Checa C, Voskuyl AE, Vonk MC, Molberg Ø, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BP, Denton CP, Fonseca C, Radstake TR, Worthington J, Mayes MD, Martín J.

Arthritis Rheumatol. 2016 Sep;68(9):2338-44. doi: 10.1002/art.39730.

34.

Effectiveness of an integrated care intervention on supervisor support and work functioning of workers with rheumatoid arthritis.

van Vilsteren M, Boot CR, Twisk JW, van Schaardenburg D, Steenbeek R, Voskuyl AE, Anema JR.

Disabil Rehabil. 2017 Feb;39(4):354-362. doi: 10.3109/09638288.2016.1145257. Epub 2016 Apr 21.

PMID:
27097657
35.

One Year Effects of a Workplace Integrated Care Intervention for Workers with Rheumatoid Arthritis: Results of a Randomized Controlled Trial.

van Vilsteren M, Boot CR, Twisk JW, Steenbeek R, Voskuyl AE, van Schaardenburg D, Anema JR.

J Occup Rehabil. 2017 Mar;27(1):128-136. doi: 10.1007/s10926-016-9639-0.

36.

Exploring thermography: a promising tool in differentiation between infection and ischemia of the acra in systemic sclerosis.

van der Weijden MAC, van Vugt LM, Valk D, Wisselink W, van Vugt RM, Voskuyl AE, Lems WF.

Int J Rheum Dis. 2017 Dec;20(12):2190-2193. doi: 10.1111/1756-185X.12859. Epub 2016 Apr 2. No abstract available.

PMID:
27038005
37.

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.

de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, van der Pouw Kraan TC, Leurs C, Hegen H, Deisenhammer F, Killestein J, Lundberg IE, Vencovsky J, Nurmohamed MT, van Schaardenburg D, Bultink IE, Voskuyl AE, Pegtel DM, van der Laken CJ, Bijlsma JW, Verweij CL.

Arthritis Res Ther. 2016 Feb 17;18:49. doi: 10.1186/s13075-016-0946-9.

38.

Comparing inflammatory cell density in the myocardium and coronary arteries in rheumatoid arthritis patients versus controls with myocardial infarction: A post-mortem case-control study.

van den Oever IA, van Sijl AM, Baylan U, Ter Wee MM, Schalkwijk CG, Krijnen PA, Nurmohamed MT, Voskuyl AE, Niessen HW, Simsek S.

Int J Cardiol. 2016 Apr 15;209:74-6. doi: 10.1016/j.ijcard.2016.02.065. Epub 2016 Feb 3. No abstract available.

39.

An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases.

Smith V, Beeckman S, Herrick AL, Decuman S, Deschepper E, De Keyser F, Distler O, Foeldvari I, Ingegnoli F, Müller-Ladner U, Riccieri V, Riemekasten G, Sulli A, Voskuyl A, Cutolo M; EULAR study group on microcirculation.

Rheumatology (Oxford). 2016 May;55(5):883-90. doi: 10.1093/rheumatology/kev441. Epub 2016 Feb 3.

PMID:
26843483
40.

Process Evaluation of a Workplace Integrated Care Intervention for Workers with Rheumatoid Arthritis.

van Vilsteren M, Boot CR, Voskuyl AE, Steenbeek R, van Schaardenburg D, Anema JR.

J Occup Rehabil. 2016 Sep;26(3):382-91. doi: 10.1007/s10926-015-9624-z.

41.

Sensing of latent EBV infection through exosomal transfer of 5'pppRNA.

Baglio SR, van Eijndhoven MA, Koppers-Lalic D, Berenguer J, Lougheed SM, Gibbs S, Léveillé N, Rinkel RN, Hopmans ES, Swaminathan S, Verkuijlen SA, Scheffer GL, van Kuppeveld FJ, de Gruijl TD, Bultink IE, Jordanova ES, Hackenberg M, Piersma SR, Knol JC, Voskuyl AE, Wurdinger T, Jiménez CR, Middeldorp JM, Pegtel DM.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E587-96. doi: 10.1073/pnas.1518130113. Epub 2016 Jan 14.

42.

Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis.

Tsang-A-Sjoe MW, Nagelkerke SQ, Bultink IE, Geissler J, Tanck MW, Tacke CE, Ellis JA, Zenz W, Bijl M, Berden JH, de Leeuw K, Derksen RH, Kuijpers TW, Voskuyl AE.

Rheumatology (Oxford). 2016 May;55(5):939-48. doi: 10.1093/rheumatology/kev433. Epub 2016 Jan 8.

PMID:
26748351
43.

Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

de Groot KA, Tsang A Sjoe M, Niewerth D, Cloos J, Blank JL, Niessen HW, Zweegman S, Voskuyl AE, Jansen G, van der Heijden JW.

Lupus Sci Med. 2015 Dec 18;2(1):e000121. doi: 10.1136/lupus-2015-000121. eCollection 2015.

44.

FSAP-mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE.

Marsman G, Stephan F, de Leeuw K, Bulder I, Ruinard JT, de Jong J, Westra J, Bultink IE, Voskuyl AE, Aarden LA, Luken BM, Kallenberg CG, Zeerleder S.

Eur J Immunol. 2016 Mar;46(3):762-71. doi: 10.1002/eji.201546010. Epub 2015 Dec 22.

45.

Remission in SLE: closing in on the target.

van Vollenhoven RF, Voskuyl A, Morand E, Aranow C.

Ann Rheum Dis. 2015 Dec;74(12):2103-6. doi: 10.1136/annrheumdis-2015-208231. Epub 2015 Oct 28. No abstract available.

PMID:
26511997
46.

Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study.

Gent YY, Ter Wee MM, Voskuyl AE, den Uyl D, Ahmadi N, Dowling C, van Kuijk C, Hoekstra OS, Boers M, Lems WF, van der Laken CJ.

Arthritis Res Ther. 2015 Sep 25;17:266. doi: 10.1186/s13075-015-0770-7.

47.

The association between FOK-I vitamin D receptor gene polymorphisms and bone mineral density in patients with systemic lupus erythematosus.

Jacobs J, Voskuyl AE, Korswagen LA, Theunissen R, Cohen Tervaert JW, Bultink IE.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5):765. Epub 2015 Sep 22. No abstract available.

PMID:
26394116
48.

Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway.

López-Isac E, Campillo-Davo D, Bossini-Castillo L, Guerra SG, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, García de la Peña P; Spanish Scleroderma Group, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, de Vries-Bouwstra J, Herrick A, Worthington J, Denton CP, Fonseca C, Radstake TR, Mayes MD, Martín J.

Ann Rheum Dis. 2016 Aug;75(8):1521-6. doi: 10.1136/annrheumdis-2015-208154. Epub 2015 Sep 2.

49.

Effective Treatment for Rapid Improvement of Both Disease Activity and Self-Reported Physical Activity in Early Rheumatoid Arthritis.

Konijn NP, van Tuyl LH, Boers M, den Uyl D, Ter Wee MM, Kerstens P, Voskuyl AE, Nurmohamed M, van Schaardenburg D, Lems WF.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):280-4. doi: 10.1002/acr.22668.

50.

Productivity at work and quality of life in patients with rheumatoid arthritis.

van Vilsteren M, Boot CR, Knol DL, van Schaardenburg D, Voskuyl AE, Steenbeek R, Anema JR.

BMC Musculoskelet Disord. 2015 May 6;16:107. doi: 10.1186/s12891-015-0562-x.

Supplemental Content

Loading ...
Support Center